INFI - Infinity Pharmaceuticals Announces Conference Call for the ASCO Genitourinary Cancers Symposium to Discuss Clinical Data from MARIO-275 Phase 2 Study
Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that it will hold a conference call on Thursday, February 11, 2021 at 7:30 a.m. ET to discuss clinical data from MARIO-275 ( Ma crophage R eprogramming In I mmuno- O ncology), a Phase 2 randomized, placebo-controlled study of eganelisib combined with Opdivo ® (nivolumab) in I/O naïve urothelial cancer.
Conference Call Information
A live webcast of the conference call can be accessed in the "Investors/Media" section of Infinity's website at www.infi.com . To participate in the conference call, please dial (877) 316-5293 (domestic) and (631) 291-4526 (international) five minutes prior to start time. The conference ID number is 2485636. An archived version of the webcast will be available on Infinity's website for 30 days.
| ASCO Genitourinary Cancers Symposium Poster Presentation Details |
|
|
|
|
| Title: |
|
|
|
|
| Preliminary Analysis of a Phase 2, Multicenter, Randomized, active-Control Study to Evaluate the Efficacy and Safety of Eganelisib (IPI-549) in Combination with Nivolumab Compared to Nivolumab Monotherapy in Patients with Advanced Urothelial Carcinoma |
| Presenter: |
|
|
|
|
| Piotr Tomczak, M.D., Ph.D. |
| Date: |
|
|
|
|
| February 11 th at 8am ET |
About Infinity and Eganelisib
Infinity is an innovative biopharmaceutical company dedicated to developing novel medicines for people with cancer. Infinity is advancing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a Phase 2, randomized, placebo-controlled study of eganelisib combined with Opdivo in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq ® and Abraxane ® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil ® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com .
Opdivo ® is a registered trademark of Bristol Myers Squibb.
Tecentriq ® is a registered trademark of Genentech, Inc.
Abraxane ® is a registered trademark of Abraxis BioScience, LLC a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin ® is a registered trademark of Genentech, Inc.
Doxil ® is a registered trademark of Baxter Healthcare Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005916/en/
Investor Relations Contact:
Ashley Robinson
LifeSci Advisors, LLC
617-775-5956